Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.
Roger Stupp
Consultant or Advisory Role - Merck Serono; Merck Sharp & Dohme; Roche/Genentech
Honoraria - Merck Serono; Merck Sharp & Dohme; Roche/Genentech
Monika E. Hegi
Consultant or Advisory Role - MDxHealth; MSD
Honoraria - MDxHealth; MSD
Research Funding - MDxHealth
Thierry Gorlia
No relevant relationships to disclose
Sara Erridge
No relevant relationships to disclose
Danica Grujicic
No relevant relationships to disclose
Joachim Peter Steinbach
Consultant or Advisory Role - Roche
Research Funding - Merck KGaA
Wolfgang Wick
Consultant or Advisory Role - Magforce; MSD; Roche
Honoraria - MSD; Roche
Research Funding - Boehringer Ingelheim; Lilly; MSD; Roche
Rafal Tarnawski
No relevant relationships to disclose
Do-Hyun Nam
No relevant relationships to disclose
Astrid Weyerbrock
No relevant relationships to disclose
Peter Hau
No relevant relationships to disclose
Martin JB Taphoorn
Consultant or Advisory Role - Roche
Honoraria - Roche
Louis B. Nabors
No relevant relationships to disclose
David A. Reardon
Consultant or Advisory Role - Amgen; EMD Serono; Merck; Novartis; Roche/Genentech
Honoraria - EMD Serono; Merck; Roche/Genentech
Martin J. Van Den Bent
Consultant or Advisory Role - Merck Serono; MSD; Roche; Siena Biotech
Honoraria - MSD
Research Funding - Roche
James R. Perry
Honoraria - Merck
Yong Kil Hong
No relevant relationships to disclose
Christine Hicking
Employment or Leadership Position - Merck KGaA
Stock Ownership - Merck KGaA
Martin Picard
Employment or Leadership Position - Merck KGaA
Michael Weller
Consultant or Advisory Role - Antisense Pharma; Merck Serono; Roche
Honoraria - Merck Serono; MSD; Roche
Research Funding - Antisense Pharma; Merck Serono; MSD; Roche